Neoadjuvant immunotherapy in melanoma – the new frontier

Menzies AM, Scolyer RA, Long GV. Clin Cancer Res. (Epub 3 June 2021)


Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.